CreoESG is expanding the application fields of its universal vaccine development platform, ‘SUV-MAP.’ On the 14th, CreoESG announced that it has begun developing immuno-oncology drugs based on SUV-MAP.
CreoESG plans to develop immuno-oncology drugs using the advanced SUV-MAP. The vector (delivery vehicle) of SUV-MAP carries antigens, and the basic structure of vectors for vaccines and immuno-oncology drugs is similar. CreoESG intends to enhance SUV-MAP to target specific cancer types, applying the technology secured through the development of various viral vaccines to the field of anticancer drugs as well.
CreoESG possesses ‘recombinant vesicular stomatitis virus (rVSV)’ technology that does not cause disease. SUV-MAP incorporating rVSV technology is characterized by high safety due to its limited replication at human body temperature, and it directly stimulates T cells and B cells, resulting in excellent immune responses. The company explains that developing immuno-oncology drugs using SUV-MAP can minimize side effects by attacking only specific cancer cells, and it will be easy to expand into various anticancer drug developments in the future.
A CreoESG representative said, “We have been reviewing various options to diversify new drug development areas by utilizing existing vaccine-related technologies, and we decided to enter the immuno-oncology market, which has the highest technical similarity first. We plan to develop immuno-oncology drugs targeting breast cancer, colorectal cancer, and skin cancer, and are preparing to establish a new research institute and recruit experts for full-scale development.”
He added, “To maximize the therapeutic effects of immuno-oncology drugs, we plan to conduct research on various immune boosters and complex efficacy enhancement in parallel. In addition to vaccines such as AIDS vaccines, we will accelerate anticancer drug development based on the SUV-MAP platform to secure new growth engines.”
According to the global market research firm Grand View Research, the global market size for immuno-oncology drugs is expected to grow from $136.1 billion (approximately 186 trillion KRW) this year at an average annual growth rate of 8.3%, reaching $219.6 billion (approximately 300 trillion KRW) by 2030.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
